Apotex Withdraws 31 ANDAs After Failing To Ensure Data Integrity At Two Indian Manufacturing Plants

 
• By Bowman Cox

Persistent data integrity and quality unit failures at two Apotex plants in Bangalore, India, led to wholesale US market withdrawals by the Canadian generic drug manufacturer.

withdrawn-stamp
data lapses eventually undermined approvals

More from Generics

More from Biosimilars & Generics